Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-225289 in adults with ADHD
NCT01692782Phase 2Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Dec 2012
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dasotraline in attention deficit hyperactivity disorder (ADHD), sponsored by Sumitomo Pharma America. Started Dec 2012; status: completed.
02
Drugs
dasotraline
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01692782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01692782.